Singapore markets open in 9 hours
Straits Times Index
3,218.17 +13.60 (+0.42%) S&P 500
4,572.38 -2.41 (-0.05%) Dow
35,626.69 -130.19 (-0.36%) Nasdaq
15,306.63 +70.91 (+0.47%) BTC-USD
58,820.77 -3,744.76 (-5.99%) CMC Crypto 200
1,414.13 -60.20 (-4.08%)
Galapagos NV (GLPG)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
52.12-0.38 (-0.72%)
As of 11:54AM EDT. Market open.
| Previous close | 52.50 |
| Open | 52.75 |
| Bid | 51.96 x 900 |
| Ask | 52.10 x 900 |
| Day's range | 51.91 - 52.79 |
| 52-week range | 48.66 - 129.03 |
| Volume | 56,568 |
| Avg. volume | 242,363 |
| Market cap | 3.44B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.46 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 79.80 |
- Zacks
Galapagos (GLPG) Concludes Enrollment in Crohn's Disease Study
Galapagos (GLPG) finishes enrollment in phase III study evaluating filgotinib for Crohn's Disease. The company also assumes sole responsibility for the DIVERSITY study.
- Motley Fool
Galapagos NV (GLPG) Q2 2021 Earnings Call Transcript
GLPG earnings call for the period ending June 30, 2021.
- Motley Fool
Here's Why Galapagos Stock Is Falling Today
Shares of Galapagos (NASDAQ: GLPG), a biopharmaceutical company, are under pressure following clinical trial readouts for a couple of new drug candidates in phase 1 studies. Disappointing results from the company's Toledo program pushed the stock 13.1% lower as of 3:52 p.m. EDT on Thursday. Following the implosion of Jyseleca in the U.S., Galapagos has leaned on its early clinical-stage pipeline to get attention from investors.
© 2021 Verizon Media. All rights reserved.
